Fingerprint
Dive into the research topics of 'Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab
Mark C. Gillies, Anna Campain, Richard Walton, Judy M. Simpson, Jennifer J. Arnold, Robyn H. Guymer, Ian L. McAllister, Alex P. Hunyor, Rohan W. Essex, Nigel Morlet, Daniel Barthelmes*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
26
Citations
(Scopus)